Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Maintenance in MDD
NCT01838681Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD) (2 arms), sponsored by Lundbeck. Primary endpoint: Full Remission During the Randomised Treatment Period at 24 weeks. Started Jun 2013; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01838681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838681.